Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile.

Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzón IM, Nepomnaschy I, Costa H, Cañones C, Raiden S, Vermeulen M, Geffner JR. · 2010

Read Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. by Maggini J, Mirkin G, Bognanni I, Holmberg J, Piazzón IM, Nepomnaschy I, Costa H, Cañones C, Raiden S, Vermeulen M, Geffner JR. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2821929.txt.

Introduction

Maggini and colleagues showed in 2010 that mouse bone marrow stromal cells can flip activated macrophages into a calming, regulatory state. Macrophages are immune eater cells that normally pour out inflammatory signals when triggered. Stromal cells are already known to quiet immune responses, one reason they interest doctors as therapy.

Placed with triggered macrophages, stromal cells cut output of four inflammatory signals and raised a calming one, IL-10. A fat-like messenger the stromal cells release constantly, called PGE2, drove much of the effect, since aspirin blocked it. The flipped macrophages also ate dead cells better and presented far fewer flags to T cells. One downside stood out: they became far easier for a parasite to infect.

Catalog record

CREATORMaggini J, Mirkin G, Bognanni I, Holmberg J, Piazzón IM, Nepomnaschy I, Costa H, Cañones C, Raiden S, Vermeulen M, Geffner JR.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE66 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2821929

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mouse Bone Marrow-Derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-Like Profile By Julian Maggini, Gerardo Mirkin, Ianina Bognanni, Josefina Holmberg, Isabel M. Piazzón, Irene Nepomnaschy, Héctor Costa, Cristian Cañones, Silvina Raiden, Mónica Vermeulen, Jorge R. Geffner, Olivier Neyrolles Published in: PLoS ONE DOI: 10.1371/journal.pone.0009252 ABSTRACT In recent years it has become clear that the therapeutic properties of bone marrow-derived mesenchymal stromal cells (MSC) are related not only to their ability to differentiate into different lineages but also to their capacity to suppress the immune response. We here studied the influence of MSC on macrophage function. Using mouse thioglycolate-elicited peritoneal macrophages (M) stimulated with LPS, we found that MSC markedly suppressed the production of the inflammatory cytokines TNF-α, IL-6, IL-12p70 and interferon-γ while increased the production of IL-10 and IL-12p40. Similar results were observed using supernatants from MSC suggesting that factor(s) constitutively released by MSC are involved. Supporting a role for PGE2 we observed that acetylsalicylic acid impaired the ability of MSC to inhibit the production of inflammatory cytokines and to stimulate the production of IL-10 by LPS-stimulated M. Moreover, we found that MSC constitutively produce PGE2 at levels able to inhibit the production of TNF-α and IL-6 by activated M. MSC also inhibited the up-regulation of CD86 and MHC class II in LPS-stimulated M impairing their ability to activate antigen-specific T CD4+ cells. On the other hand, they stimulated the uptake of apoptotic thymocytes by M. Of note, MSC turned M into cells highly susceptible to infection with the parasite Trypanosoma cruzi increasing more than 5-fold the rate of M infection. Using a model of inflammation triggered by s.c. implantation of glass cylinders, we found that MSC stimulated the recruitment of macrophages which showed a low expression of CD86 and the MHC class II molecule Iab and a high ability to produce IL-10 and IL-12p40, but not IL-12 p70. In summary, our results suggest that MSC switch M into a regulatory profile characterized by a low ability to produce inflammatory cytokines, a high ability to phagocyte apoptotic cells, and a marked increase in their susceptibility to infection by intracellular pathogens. INTRODUCTION Bone marrow-derived mesenchymal stromal cells (MSC) are pluripotent adult stromal cells able to differentiate into different cell types such as osteoblasts, chondrocytes and adipocytes [1]. These cells preferentially home to damaged tissues and therefore they have attracted scientific attention as potential therapeutic tools for tissue repair [1]–[3]. Studies performed in the last years, however, demonstrated that MSC exert potent immunomodulatory effects and support the notion that the therapeutic potential of MSC is not only related to their ability to differentiate into different lineages but also to their capacity to suppress the immune response [4], [5]. A larger number of studies mainly performed in vitro have shown that MSC display immunomodulatory capacities. MSC inhibit the differentiation of monocytes and CD34+ haematopoietic progenitor cells into dendritic cells (DC) [6], [7]. They suppress the maturation of DC and the ability of DC to produce inflammatory cytokines as well as T helper-type 1 (Th1)-promoting cytokines such as IL-12p70 [6]–[9]. MSC inhibit cytotoxicity and production of interferon-γ by NK cells [10], [11], and also exert a potent immunosuppressive effect on T cells. They suppress T-cell proliferation induced by alloantigens, mitogens and soluble antigens [12]–[14]. Interestingly, this inhibition appears to be not MHC restricted as it can be induced by either autologous or allogeneic MSC. Other immunosuppressive effects mediated by MSC on T cells include down regulation of T-CD8+-mediated cytotoxicity [15] and expansion of regulatory T cells [16]. MSC are also able to regulate B cell function, suppressing both, proliferation of B cells in response to anti-Ig antibodies, soluble CD40, and cytokines, and antibody production [17], [18]. The mechanisms underlying the immunosuppressive effects mediated by MSC are not fully defined, but they appear to be largely mediated by a number of soluble factors produced by MSC, either constitutively or in response to paracrine signals derived from leukocytes. These soluble mediators include transforming growth factor-β1 (TGFβ1), hepatocyte growth factor, PGE2, indoleamine 2,3-dioxygenase (IDO), haem oxygenase-1, soluble HLA-G5, IL-10 and IL-6 [4], [5], [14]. Little is known about the effect of MSC on macrophages, a critical player of the innate immune response involved in almost all immune-mediated diseases. In the present study we analyzed this subject. We show here that MSC turns activated macrophages into a regulatory profile characterized by a low ability to produce inflammatory cytokines, a high ability to phagocyte apoptotic cells, and a dramatic increase in their susceptibility to infection with the parasite Trypanosoma cruzi (T. cruzi). MATERIALS AND METHODS Mice All experiments were conducted using 2-mo-old virgin female C57BL/6 mice or ovalbumin (OVA)-specific, MHC II-restricted, T-cell-receptor transgenic mice (OT-II mice). OT-II mice carry a transgenic CD4 TCR specific for the MHC class II-restricted OVA peptide aa 323–339. Mice were housed six per cage and kept at 20±2°C under automatic 12-h light-dark schedule. All animal experiments were performed according to the NIH Guide for the Care and Use of Laboratory Animals and approved by the ethical committee of the “Instituto de Leucemia Experimental” (ILEX) (Academia Nacional de Medicina, Buenos Aires, Argentina). Mouse MSC cultures MSC were isolated and cultured using standard protocols [19]. Bone marrow cells from C57BL/6 mice were collected by flushing the femurs and tibias from 8–12-week-old mice with RPMI medium supplemented with 5% heat-inactivated fetal calf serum (FCS) (Invitrogen, CA, USA). Erythrocytes-depleted bone marrow cells were plated at a density of 4×106 cells per cm2 in RPMI medium supplemented with 10% FCS, 100 IU/ml penicillin and 100 µg/ml streptomycin (Invitrogen). Culture medium was changed at day 2 to remove nonadherent cells. Whole medium was subsequently replaced weekly. The cells were grown for 3–4 weeks until almost confluent. Adherent cells were then detached by 0.25% trypsin-EDTA and replated using a 1∶3 dilution until passage 2. Subsequent passaging and seeding of the cells were performed at a density of 5,000 cells per cm2. MSC were used after 4–7 passages. Analysis of MSC Osteogenic and adipogenic differentiation assays were performed as previously described [20]. For standard osteogenic differentiation, confluent monolayers of MSC were incubated in medium supplemented with 10−8 M dexamethasone, 50 µM ascorbic acid, and 10 mM β-glycerol phosphate (Sigma-Aldrich, Buenos Aires, Argentina) with changes of medium every 5 days. After 30 days the cultures were fixed with 70% cold ethanol for 1 h at room temperature, and incubated with Alizarin Red S (2% aqueous solution, pH 4.1–4.3, adjusted with ammonium hydroxide) for 30 min. Excess stain was removed by washing four times with water. For standard adipogenic differentiation, confluent monolayers of MSC were incubated in medium supplemented with 10−8 M dexamethasone and 10−4 M L-ascorbic acid 2-phosphate (Sigma-Aldrich) with changes of medium every 5 days. After 30 days, the cultures were fixed in 3% formaldehyde in PBS for 10 minutes and stained with Oil Red O. The phenotype of MSC was analyzed by flow cytometry using a FACScan flowcytometer (BD Biosciences, NJ, USA). The following mAb were used: fluorescein isothiocyanate (FITC)-labeled anti-CD3, anti-B220, anti-CD31, anti-TER119, anti-SCA-1, anti-CD90, phycoerythrin (PE)-labeled anti-CD11b, anti-GR1, anti-CD45, anti-CD11c, anti-Ly6C, and anti-CKIT (BD Biosciences). Isotype controls were used in all cases. To block unspecific antibody binding cells were pre-treated for 30 min at 4°C with saturating

Read the complete text